Wirkt Levosimendan bei der operativen Versorgung des akuten Koronarsyndroms inoprotektiv?

Zusammenfassung

Levosimendan ist ein Kalzium-Sensitiser mit zwei Hauptwirkungen. Zum einen ist Levosimendan durch Kalzium abhängige Bindung an das Troponin C eine positiv inotrope Substanz. Darüber hinaus aktiviert Levosimendan die ATP abhängigen Kalium-Kanäle (K_ATP-Kanäle). Durch die Aktivierung der K_ATP-Kanäle übt Levosimendan in einer Dosierung, die positiv inotrop wirkt, eine Myokardprotektion und auch Vasodilatation aus. Aufgrund dieser Eigenschaften scheint Levosimendan bei Patienten mit akuter myokardialer Ischämie, die gleichzeitig eine positiv inotrope Unterstützung benötigen, sehr vorteilhaft zu sein. Anhand von sechs Fallberichten wird das Konzept der perioperativen Inoprotektion bei akutem Koronarsyndrom vorgestellt.

Abstract

Levosimendan, is a new calcium sensitiser with 2 major effects. First, levosimendan acts as a positive inotropic agent by binding calcium dependently to cardiac troponin C. Second, levosimendan activates adenosine triphosphate-regulated potassium (K_ATP) channels. Thus it has vasodilatory properties and cardioprotective effects at a dose enhancing myocardial contractility. These unique properties of levosimendan might be of great advantage in patients with myocardial ischemia simultaneously requiring inotropic support. The concept of perioperative inoprotection is presented in 6 patients with acute ischemia undergoing emergent cardiac surgery.

Levosimendan - Kardioprotektion - myokardiale Ischämie - Herzchirurgie

Levosimendan - cardioprotection - myocardial ischemia - cardiac surgery

Literatur

• 1 Remme W J, Swedberg K. and the Task Force for the Diagnosis and Treatment of Chronic Heart Failure European Society of Cardiology .Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001 22: 1527-1560
• 2 Haikala H, Kaivola J, Nissinen E, Wall P, Levijoki J, Linden I B. Cardiac troponin C as a target protein for novel calcium sensitizing drug, levosimendan.  J Moll Cell Cardiol. 1995;  27 1859-1866
• 3 Sorsa T, Heikkinen S, Abbott M B, Abusamhadneh E, Laakso T, Tilgmann C, Serimaa R, Annila A, Rosevear P R, Drakenberg T, Pollesello P, Kilpelainen I. Binding of levosimendan, a calcium sensitizer, to cardiac troponin C.  J Biol Chem. 2001;  276 9337-9343
• 4 Janssen P M, Datz N, Zeitz O, Hasenfuss G. Levosimendan improves diastolic and systolic function in failing human myocardium.  Eur J Pharmacol. 2000;  404 191-199
• 5 Lehtonen L A. Levosimendan: a parenteral calcium-sensitising drug with additional vasodilatory properties.  Expert Opin Investig Drugs. 2001;  10 955-970
• 6 Kersten J R, Montgomery M W, Pagel P S, Warltier D C. Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K (ATP) channels.  Anesth Analg. 2000;  90 5-11
• 7 Haikala H, Pollesello P. Calcium sensitivity enhancers.  I Drugs. 2000;  3 1199-1205
• 8 Ukkonen H, Saraste M, Akkila J, Knuuti J, Karanko M, Iida H, Lehikoinen P, Nagren K, Lehtonen L, Voipio-Pulkki L M. Myocardial efficiency during levosimendan infusion in congestive heart failure.  Clin Pharmacol Ther. 2000;  68 522-531
• 9 Lilleberg J, Nieminen M S, Akkila J, Heikkila L, Kuitunen A, Lehtonen L, Verkkala K, Mattila S, Salmenpera M. Effects of a new calcium sensitizer, levosimendan, on hemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting.  Eur J Heart. 1998;  19 660-668
• 10 Kaheinen P, Pollesello P, Levijoki J, Haikala H. Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channels.  J Cardiovasc Pharmacol. 2001;  37 367-374
• 11 Kopustinskiene D M, Pollesello P, Saris N E. Levosimendan is a mitochondrial K(ATP) channel opener.  Eur J Pharmacol. 2001;  428 311-314
• 12 Yokoshiki H, Katsube Y, Sunagawa M, Sperelakis N. The novel calcium sensitizer levosimendan activates the ATP-sensitive K⁺ channel in rat ventricular cells.  J Pharmacol Exp Ther. 1997;  283 375-383
• 13 Loubani M, Galinanes M. Pharmacological and ischemic preconditioning of the human myocardium: mitoKATP channels are upstream and p38MAPK is downstream of PKC.  BMC Physiol. 2002;  2 10
• 14 Perrault L P, Menasche P. Preconditioning: can nature’s shield be raised against surgical ischemic-reperfusion injury?.  Ann Thorac Surg. 1999;  68 1988-1994
• 15 Patel D J, Purcell H J, Fox K M. Cardioprotection by opening of the K(ATP) channels in unstable angina. Is this a clinical manifestation of myocardial preconditioning? Results of a randomized study with nicorandil. CESAR 2 investigation. Clinical European studies in angina and revascularization.  Eur Heart J. 1999;  20 51-57
• 16 Zaugg M, Lucchinetti E, Spahn D R, Pasch T, Schaub M C. Volatile anesthetics mimic cardiac preconditioning by priming the activation of mitochondrial K(ATP) channel via multiple signaling pathways.  Anesthesiology. 2002;  97 4-14
• 17 Hert S G de, Broecke P W ten, Mertens E, van Sommeren E W, de Blier I G, Stockman B A, Rodrigus I E. Sevoflurane but not propofol preserves myocardial function in coronary surgery patients.  Anesthesiology. 2002;  97 42-49
• 18 Cope D K, Impastato W K, Cohen M V, Downey J M. Volatile anesthetics protect ischemic rabbit myocardium from infarction.  Anesthesiology. 1997;  86 699-709
• 19 Jamali I N, Kersten J R, Pagel P S, Hettrick D A, Warltier D C. Intracoronary levosimendan enhances contractile function of stunned myocardium.  Anesth Analg. 1997;  85 23-29
• 20 Hochman J S, Sleeper L A, White H D, Dzavik V, Wong S C, Menon V, Webb J G, Steingart R, Picard M H, Menegus M A, Boland J, Sanborn T, Buller C E, Modur S, Forman R, Desvigne-Nickens P, Jacobs A K, Slater J N, LeJemtel T H. SHOCK Investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. One-year survival following early revascularization for cardiogenic shock.  JAMA. 2001;  285 190-192
• 21 Hasenfuss G, Pieske B, Castell M, Kretschmann B, Maier L S, Just H. Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium.  Circulation. 1998;  98 2141-2147
• 22 Hasenfuss G, Pieske B, Kretschmann B, Holubarsch C, Alpert N R, Just H. Effects of calcium sensitizers on intracellular calcium handling and myocardial energetics.  J Cardiovasc Pharmacol. 1995;  26 (Suppl 1) S45-S51
• 23 Toit E F du, Muller C A, McCarthy J, Opie L H. Levosimendan: effects of a calcium sensitizer on function and arrhythmias and cyclic nucleotide levels during ischemia/reperfusion in the Langendorff-perfused guinea pig heart.  J Pharmacol Exp Ther. 1999;  290 505-514
• 24 Carnendran L, Abboud R, Sleeper L A, Gurunathan R, Webb J G, Menon V, Dzavik V, Cocke T, Hochman J S. Trends in cardiogenic shock: report from the SHOCK study. Should we emergently revascularize occluded coronaries for cardiogenic shock?.  Eur Heart J. 2001;  22 472-478
• 25 Thompson C R, Buller C E, Sleeper L A, Antonelli T A, Webb J G, Jaber W A, Abel J G, Hochman J S. Cardiogenic shock due to acute severe mitral regurgitation complicating acute myocardial infarction: a report from the SHOCK trial registry. Should we emergently revascularize occluded coronaries for cardiogenic shock?.  J Am Coll Cardiol. 2000;  36 (3 Suppl A) 1104-1109
• 26 McGough M F, Pagel P S, Lowe D, Hettrick D A, Warltier D C. Levosimendan potentiates the inotropic actions of dopamine in conscious dogs.  J Cardiovasc Pharmacol. 1996;  28 36-47
• 27 Muller M, Junger A, Brau M, Kwapisz M M, Schindler E, Akinturk H, Benson M, Hempelmann G. Incidence and risk calculation of inotropic support in patients undergoing cardiac surgery with cardiopulmonary bypass using an automated anaesthesia record-keeping system.  Br J Anaesth. 2002;  89 398-404
• 28 Michalopoulos A, Tzelepis G, Dafni U, Geroulanos S. Determinants of hospital mortality after coronary artery bypass grafting.  Chest. 1999;  115 1598-1603
• 29 Pataricza J, Hohn J, Petri A, Balogh A, Papp J G. Comparison of the vasorelaxing effect of cromkalim and the new inodilator, levosimendan, in human isolated portal vein.  J Pharm Pharmacol. 2000;  52 213-217
• 30 de Witt B J, Ibrahim I N, Bayer E, Fields A M, Richards T A, Banister R E, Kaye A D. An analysis of the responses to levosimendan in the pulmonary vascular bed of the cat.  Anesth Analg. 2002;  94 1427-1433
• 31 Nijhawan N, Nicolosi A C, Montgomery M W, Aggarwal A, Pagel P S, Warltier D C. Levosimendan enhances cardiac performance after cardiopulmonary bypass: a prospective, randomized placebo-controlled trial.  J Cardiovasc Pharmacol. 1999;  34 219-228
• 32 Moiseyev V S, Poder P, Andrejevs N, Ruda M Y, Golikov A P, Lazebnik L B, Kobalava Z D, Lehtonen L A, Laine T, Nieminen M S, Lie K I. RUSSLAN Study Investigators: Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN).  Eur Heart J. 2002;  23 1422-1432
• 33 Lethonen L. Levosimendan: A promising agent for the treatment of hospitalized patients with decompensated heart failure.  Curr Cardiol Rep. 2000;  2 233-243